10 completed, 2 unknown, 1 withdrawn. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 10, Unknown 2, Withdrawn 1 |
Follow rt-PA: new trials by email Literature Review of rt-PA trials Research Report on rt-PA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 Tenecteplase, Best Practice (which may include intravenous Alteplase) - Ischemic Stroke, Acute | Phase 3 | Completed | Beijing Tiantan Hospital | 452 | 2024-01-24 | 2025-11-26 |
| rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) rhPro-UK, rt-PA - Acute Ischemic Stroke | Phase 3 | Completed | Tasly Biopharmaceuticals Co., Ltd. | 1552 | 2023-01-29 | 2024-07-26 |
| Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） Alteplase, Tenecteplase - Acute Ischemic Stroke | Phase 3 | Unknown | Beijing Tiantan Hospital | 1630 | 2022-10-26 | 2023-02-27 |
| A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） Injection of recombinant human tissue plasminogen kinase derivatives, Recombinant human tissue plasminogen activator - Acute Ischemic Stroke | Phase 3 | Completed | Angde Biotech Pharmaceutical Co., Ltd. | 1412 | 2022-03-21 | 2024-03-04 |
| Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ rt-PA, rhTNK-tPA - Acute Ischemic Stroke | Phase 3 | Completed | Beijing Tiantan Hospital | 1430 | 2021-06-12 | 2023-01-17 |
| Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial Recombinant tissue plasminogen activator (rt-PA), Standard Anticoagulation Therapy - Deep Vein Thrombosis, Post-Thrombotic Syndrome | Phase 3 | Withdrawn | University of Colorado, Denver | 2018-07-01 | 2018-08-10 | |
| Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) Recombinant human urokinase, Alteplase - Acute Ischaemic Stroke | Phase 3 | Completed | Tasly Biopharmaceuticals Co., Ltd. | 674 | 2018-05-18 | 2020-06-22 |
| THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS) Tissue-type plasminogen activator (alteplase), Standard care - Stroke | Phase 3 | Unknown | National Cerebral and Cardiovascular Center, Japan | 300 | 2014-05-01 | 2018-12-20 |
| Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III rt-PA - Intracerebral Hemorrhage | Phase 3 | Completed | Johns Hopkins University | 499 | 2013-12-30 | 2019-09-27 |
| Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke Alteplase, Placebo - Stroke | Phase 3 | Completed | Universitätsklinikum Hamburg-Eppendorf | 501 | 2012-09-01 | 2018-10-11 |
| Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Recombinant tissue plasminogen activator (rt-PA) - Deep Vein Thrombosis, Venous Thrombosis | Phase 3 | Completed | Washington University School of Medicine | 692 | 2009-11-01 | 2018-03-29 |
| Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III Alteplase, Normal saline - Intraventricular Hemorrhage | Phase 3 | Completed | Johns Hopkins University | 500 | 2009-07-01 | 2018-12-05 |
| Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction TNK-tPA, rt-PA - Myocardial Infarction | Phase 3 | Completed | Boehringer Ingelheim | 270 | 2001-03-01 | 2013-10-29 |
Ischemic Stroke (6) · Stroke (4) · Postthrombotic Syndrome (2) · Thrombosis (2) · Venous Thrombosis (2) · Cerebral Hemorrhage (1) · Intracranial Hemorrhages (1) · Myocardial Infarction (1) · Postphlebitic Syndrome (1) · Venous Thromboembolism (1)
Beijing Tiantan Hospital (3) · Johns Hopkins University (2) · Tasly Biopharmaceuticals Co., Ltd. (2) · Angde Biotech Pharmaceutical Co., Ltd. (1) · Boehringer Ingelheim (1) · National Cerebral and Cardiovascular Center, Japan (1) · University of Colorado, Denver (1) · Universitätsklinikum Hamburg-Eppendorf (1) · Washington University School of Medicine (1)
China (8) · Germany (3) · Spain (3) · United Kingdom (3) · United States (3) · Canada (2) · Hungary (2) · Israel (2) · Australia (1) · Belgium (1) · Brazil (1) · Denmark (1) · France (1) · Hong Kong (1) · Japan (1)
Daniel F. Hanley, MD (2) · Bruce Campbell, MD, PhD (1) · Christian Gerloff, MD (1) · Clive Kearon, MB, MRCP, FRCP(C), PhD (1) · Fana Alemseged, MD, PhD (1) · Goetz Thomalla, MD (1) · Issam Awad, MD (1) · Kazunori Toyoda, MD (1) · Marilyn J Manco-Johnson, MD (1) · Mario Zuccarello, MD (1) · Samuel Z Goldhaber, M.D. (1) · Shuya Li (1) · Suresh Vedantham, M.D. (1) · Wei Sun (1)
PMID 29766770, PMID 38907679, PMID 20047905, PMID 22435369, PMID 23537968, PMID 24324944, PMID 25517348, PMID 25671797, PMID 25671798, PMID 25677596, PMID 25882376, PMID 25882510, PMID 26243227, PMID 26898852, PMID 27462117, PMID 28081952, PMID 28174327, PMID 28425349, PMID 28842449, PMID 28887375, PMID 29211671, PMID 29367334, PMID 29694815, PMID 30586751, PMID 30699446, PMID 30739747, PMID 31067369, PMID 31161343, PMID 31177984, PMID 31354089, PMID 31571176, PMID 31592728, PMID 31662117, PMID 31824412, PMID 31843251, PMID 32026447, PMID 32248771, PMID 32561535, PMID 32562685, PMID 33297866, PMID 33324925, PMID 33445952, PMID 33613422, PMID 33657675, PMID 33980046, PMID 34414292, PMID 34433305, PMID 34446531, PMID 34782419, PMID 34937780
U01HL088476 (1), U01NS062851 (1), U01NS080824 (1)